Local Anesthetics Have Different Mechanisms and Sites of Action at Recombinant 5-HT3 Receptors

Regional Anesthesia and Pain Medicine

Volumn 32, Issue 6, 2007, Pages 462-470

  Ueta, Kazuyoshi ^a   Suzuki, Takahiro ^a   Sugimoto, Masahiro ^a   Uchida, Ichiro ^a   Mashimo, Takashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Electrophysiology; Oocyte; Recombinant; Site directed mutagenesis; Subunit

Indexed keywords

ASPARAGINE; ASPARTIC ACID; BUPIVACAINE; GLUTAMIC ACID; LIDOCAINE; LOCAL ANESTHETIC AGENT; METOCLOPRAMIDE; PROCAINE; RAMOSETRON; RECOMBINANT RECEPTOR; RNA; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 3A RECEPTOR; TETRACAINE; TRICAINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG COMPETITION; DRUG MECHANISM; ELECTRIC CURRENT; ELECTRODE; FEMALE; IN VITRO STUDY; LOCAL ANESTHESIA; MOLECULAR CLONING; MUTANT; NONHUMAN; OOCYTE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VOLTAGE CLAMP; WILD TYPE; XENOPUS LAEVIS;

ALGORITHMS; AMINO ACID SEQUENCE; ANESTHETICS, LOCAL; ANIMALS; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; HUMANS; MEMBRANE POTENTIALS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; OOCYTES; PATCH-CLAMP TECHNIQUES; RECEPTORS, SEROTONIN, 5-HT3; RECOMBINANT PROTEINS; SEROTONIN ANTAGONISTS; XENOPUS;

EID: 36148999470     PISSN: 10987339     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rapm.2007.06.391     Document Type: Article

References (24)

1. Marica L.S., O'Day T., Janosky J.E., and Nystrom E.U. Chloroprocaine is less painful than lidocaine for skin infiltration anesthesia. Anesth Analg 94 (2002) 351-354
2. Prien T. Intradermal anaesthesia: comparison of several compounds. Acta Anaesthesiol Scand 38 (1994) 805-807
3. Pang W.W., Mok M.S., Chang D.P., and Huang M.H. Local anesthetic effect of tramadol, metoclopramide, and lidocaine following intradermal injection. Reg Anesth Pain Med 23 (1998) 580-583
4. Gwirtz K.H., Young J.V., Byers R.S., Alley C., Levin K., Walker S.G., and Stoelting R.K. The safety and efficacy of intrathecal opioid analgesia for acute postoperative pain: seven years' experience with 5969 surgical patients at Indiana University Hospital. Anesth Analg 88 (1999) 599-604
5. Szarvas S., Harmon D., and Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth 15 (2003) 234-239
6. Iatrou C.A., Dragoumanis C.K., Vogiatzaki T.D., Vretzakis G.I., Simopoulos C.E., and Dimitriou V.K. Prophylactic intravenous ondansetron and dolasetron in intrathecal morphine-induced pruritus: a randomized, double-blinded, placebo-controlled study. Anesth Analg 101 (2005) 1516-1520
7. Wu J.L., Hsu M.S., Hsu T.C., Chen L.H., Yang W.J., and Tsai Y.C. The efficacy of intrathecal coadministration of morphine and bupivacaine for labor analgesia. Acta Anaesthesiol Sin 35 (1997) 209-216
8. Mulroy M.F., Larkin K.L., and Siddiqui A. Intrathecal fentanyl-induced pruritus is more severe in combination with procaine than with lidocaine or bupivacaine. Reg Anesth Pain Med 26 (2001) 252-256
9. Barann M., Göthert M., Fink K., and Bönisch H. Inhibition by anesthetics of 14C-guanidinium flux through the voltage-gated sodium channel and the cation channel of the 5-HT3 receptor of N1E-115 neuroblastoma cells. Naunyn Schmiedebergs Arch Pharmacol 347 (1993) 125-132
10. Faerber L., Drechsler S., Ladenburger S., Gschaidmeier H., and Fischer W. The neuronal 5-HT3 receptor network after 20 years of research-evolving concepts in management of pain and inflammation. Eur J Pharmacol 560 (2007) 1-8
11. Giordano J., and Schultea T. Serotonin 5-HT(3) receptor mediation of pain and anti-nociception: implications for clinical therapeutics. Pain Physician 7 (2004) 141-147
12. Jackson M.B., and Yakel J.L. The 5-HT3 receptor channel. Annu Rev Physiol 57 (1995) 447-468
13. Post C., and Freedman J. A new method for studying the distribution of drugs in spinal cord after intrathecal injection. Acta Pharmacol Toxicol (Copenh) 54 (1984) 253-257
14. Berde C.B., and Strichartz G.R. Local anesthetics. In: Miller R.D. (Ed). Anesthesia. 5th ed (1999), Churchill Livingstone, Philadelphia 491-522
15. Morris R.W., and Whish D.K. A controlled trial of pain on skin infiltration with local anaesthetics. Anaesth Intensive Care 12 (1984) 113-114
16. Arias H.R. Role of LAs on both cholinergic and serotonergic ionotropic receptors. Neurosci Biobehav Rev 23 (1999) 817-843
17. Sugimoto M., Uchida I., and Mashimo T. LAs have different mechanisms and sites of action at the recombinant N-methyl-D-aspartate (NMDA) receptors. Br J Pharmacol 138 (2003) 876-882
18. Steward L.J., Boess F.G., Steele J.A., Liu D., Wong N., and Martin I.L. Importance of phenylalanine 107 in agonist recognition by the 5-hydroxytryptamine (3A) receptor. Mol Pharmacol 57 (2000) 1249-1255
19. Changeux J.P., Galzi J.L., Devillers-Thiery A., and Bertrand D. The functional architecture of the acetylcholine nicotinic receptor explored by affinity labelling and site-directed mutagenesis. Q Rev Biophys 25 (1992) 395-432
20. Boess F.G., Steward L.J., Steele J.A., Liu D., Reid J., Glencorse T.A., and Martin I.L. Analysis of the ligand binding site of the 5-HT3 receptor using site directed mutagenesis: importance of glutamate 106. Neuropharmacology 36 (1997) 637-647
21. Hope A.G., Belelli D., Mair I.D., Lambert J.J., and Peters J.A. Molecular determinants of (+)-tubocurarine binding at recombinant 5-hydroxytryptamine3A receptor subunits. Mol Pharmacol 55 (1999) 1037-1043
22. Spier A.D., and Lummis S.C. The role of tryptophan residues in the 5-hydroxytryptamine3 receptor ligand binding domain. J Biol Chem 275 (2000) 5620-5625
23. Zhong W., Gallivan J.P., Zhang Y., Li L., Lester H.A., and Dougherty D.A. From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor. Proc Natl Acad Sci U S A 95 (1998) 12088-12093
24. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125 (1998) 924-947